| Literature DB >> 23978667 |
Abstract
Hepatitis E Virus (HEV) ORF1 encodes the nonstructural polyprotein wherein a role of PCP-domain in ORF1 proteolysis and/or RNA replication still remains contested. A series of ORF1 mutants of HEV-SAR55 replicon were constructed and tested for viability in S10-3 cells. Six of PCP-'cysteine' (C457A, C459A, C471A, C472A, C481A and C483A) and three 'histidine' (H443L, H497L and H590L) mutants were lethal. Further, a highly conserved 'glycine-triad' (G815-G816-G817) in downstream X-domain, homologous to rubella virus protease-substrate (G1299-G1300-G1301) was identified where two of X-mutants (G816V and G817V) turned lethal. However, all ORF1 sequential nucleotide-mutants conserving the amino acids were viable, which clearly showed post-translational regulation of HEV replication by PCP- and X-domains. Moreover, while vector-expressed ORF1-fusion polyprotein yielded a ~191 kDa band in vitro, it produced ~78 and ~35 kDa fragments ex vivo. Collectively, the indispensability and functional effects of 'PCP-catalytic' and 'X-substrate' residues on HEV replication strongly supported a viral protease.Entities:
Keywords: Genomic replicon; HEV; Hepatitis E virus; ORF-1; Papain-like cysteine protease
Mesh:
Substances:
Year: 2013 PMID: 23978667 PMCID: PMC7125709 DOI: 10.1016/j.virusres.2013.07.020
Source DB: PubMed Journal: Virus Res ISSN: 0168-1702 Impact factor: 3.303
Fig. 1The ex vivo replication profiles (FM) of HEV replicon-constructs. (A) Replication of control replicons, representing the mutant constructs translated into GFP(+) or GFP (−) S10-3 cells. (B) Replication of ORF1 PCP-domain (n = 19) and X-domain (n = 13) mutants (Group-I: amino acid mutants; Group-II: sequential nucleotide mutants; * Koonin et al., 1992, Ropp et al., 2000).
Fig. 2A. ORF1 polyprotein amino acid sequence (partial) alignment of 77 HEV strains (GeneBank accession numbers: AB074918, AB074920, AB089824, AY575857, AY575858, AY575859, AF082843, AF060669, AY115488, AB091394, AB222182, AB246676, AB222183, AB236320, AB189071, AB189072, AB189074, AB189073, AB189075, AB189070, AP003430, AB222184, AB073912, AB248521, AB248522, AB248520, AF455784, AB074917, AB220972, AB161719, AB161718, AB220973, AB220975, AB220978, AB220977, AB220979, AB220976, AB161717, AB074915, AB091395, AB200239, AB099347, AB193176, AB097811, AB193177, AB193178; AB097812; AB220971; AB080575; AB220974; AB108537; DQ450072; AB197674, EF077630, AB197673, AY723745, AJ272108, AY594199, AB253420, DQ279091, AF028091, AF076239, AF459438, AF051830, X99441, D10330, M73218, AF444002, AF444003, L25547, L25595, L08816, M94177, D11093, X98292, AY230202 and M74506), representing genotypes 1, 2, 3 and 4. The conserved ‘G815-G816-G817’ triplet in ORF1 X-domain is shown (box). B. X-domain putative protease-substrate homology with that of RUBV where viable (green) and lethal mutations (red) are shown.
Fig. 3IP/WB analysis of HEV ORF1 expression and processing. (A) In vitro translation (anti-HA) showing a band of ∼191 kDa (lanes 1: pTriEx1.1and 2: pTriEx-ORF1). (B) Ex vivo synthesis in S10-3 cells (anti-HA) showing a band of ∼35 kDa* (lanes 1: pTriEx1.1, 2: pTriEx-ORF1and 3: standard protein marker). (C) Ex vivo synthesis in S10-3 cells (anti-His) showing a band of ∼78 kDa* (lanes 1: pTriEx-ORF1, 2: pTriEx-1.1, and 3: standard protein marker) (*Panda et al., 2000, Sehgal et al., 2006; **Ropp et al., 2000).